BridgeBio Pharma BBIO 深 沪
已收盘 01-09 16:00:00 美东时间
77.25
+3.430
+4.65%
华盛通- 最 高78.36
- 今 开74.48
- 成交量 288.94万股
- 最 低 74.46
- 昨 收 73.82
- 总市值 147.55亿
- 52周最高 78.585
- 市盈率 静 --
- 换手率 1.51%
- 52周最低 28.325
- 委 比 34.10%
- 总股本 1.91亿
- 历史最高 78.585
- 量 比 1.12
- 振 幅 5.28%
- 历史最低 4.98
- 每 手 1
- 风险率 13.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BridgeBio Oncology gains outperform rating from Raymond James
Raymond James initiated BridgeBio Oncology Therapeutics (BBOT) at outperform, noting the company is well capitalized and has several phase 1 data readouts this year. The firm set a $24 price target (~...
01-10 04:59
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
BridgeBio Oncology reports promising RAS and PI3Kα data
An announcement from BridgeBio Oncology Therapeutics ( ($BBOT) ) is now availab...
01-07 20:29
美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs
BridgeBio Oncology Therapeutics (BBOT) recently announced positive preliminary data for its three RAS and PI3Kα targeted therapies: BBO-8520, BBO-11818, and BBO-10203. BBO-8520, a KRAS G12C inhibitor, showed a 65% objective response rate and a 66% 6-month progression-free survival in NSCLC patients, with a favorable safety profile. It also demonstrated promising efficacy in combination with pembrolizumab. BBO-11818, a panKRAS inhibitor, achieved ...
01-07 12:00
美股盘后 | Vistra Energy Corp.涨4.95%，德希尼布FMC涨3.32%
Vistra Energy Corp.涨4.95%；德希尼布FMC涨3.32%；钢动态涨3.00%
01-06 07:10
BridgeBio to Participate in the J.P. Morgan Healthcare Conference
BridgeBio Pharma的联合创始人兼首席执行官Neil Kumar博士将在2026年1月12日参加第44届J.P. Morgan Healthcare Conference，并在会上发表演讲。投资者可通过BridgeBio官网观看直播或在活动后30天内观看回放。BridgeBio是一家专注于遗传病治疗方法的生物制药公司，成立于2015年，致力于通过基因医学的进步为患者带来变革性治疗方案。
01-05 12:30
BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET
BridgeBio Pharma将举办投资者网络研讨会，介绍其针对Achondroplasia的治疗药物infigratinib的临床研究进展。会议将于1月9日上午8点ET举行，由Janet Legare博士主讲，讨论该疾病的病理、现有治疗需求及infigratinib的潜力。BridgeBio的高管团队还将介绍PROPEL 3研究的最新进展，预计第一季度将公布顶线结果。会议可通过访问investor.bridgebio.com直播或回看。
01-02 12:30
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next?
Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher— here's why.
2025-12-31 23:01
美股盘后 | Roivant Sciences Ltd Ordinary Shares涨4.17%，MKS Instruments涨3.32%
Roivant Sciences Ltd Ordinary Shares涨4.17%；MKS Instruments涨3.32%；脑再生科技涨2.09%
2025-12-30 07:10
